Bristol Myers Squibb is consolidating its R&D leadership, combining research and development under Cristian Massacesi while Robert Plenge steps down as chief research officer. The company says the unified structure is designed to connect scientific discovery to clinical execution and sharpen portfolio decisions amid pipeline replenishment pressure.